Government-Owned Inventions; Availability for Licensing, 10499-10500 [2018-04701]

Download as PDF Federal Register / Vol. 83, No. 47 / Friday, March 9, 2018 / Notices (Catalogue of Federal Domestic Assistance Program No. 93.242, Mental Health Research Grants, National Institutes of Health, HHS) Dated: March 6, 2018. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–04805 Filed 3–8–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings amozie on DSK30RV082PROD with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel CuttingEdge Basic Research Awards (CEBRA) (R21). Date: March 20, 2018. Time: 12:00 p.m. to 8:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting). Contact Person: Susan O. McGuire, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Blvd., Room 4245, Rockville, MD 20852, (301) 827– 5817, mcguireso@mail.nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel Development of a Device to Objectively Measure Pain (R41/R42/R43/R44). Date: March 29, 2018. Time: 9:00 a.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852. Contact Person: Julia Berzhanskaya, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, Division of Extramural Research, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Boulevard, Room 4234, MSC 9550, Bethesda, MD 20892, 301–827–5840, julia.berzhanskaya@nih.gov. VerDate Sep<11>2014 16:47 Mar 08, 2018 Jkt 244001 Name of Committee: National Institute on Drug Abuse Special Emphasis Panel HIVassociated Neuropathic Pain and Opioid Interaction (R01). Date: March 29, 2018. Time: 11:00 a.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call). Contact Person: Julia Berzhanskaya, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, Division of Extramural Research, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Boulevard, Room 4234, MSC 9550, Bethesda, MD 20892, 301–827–5840, julia.berzhanskaya@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: March 6, 2018. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–04804 Filed 3–8–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel; BRAIN Initiative: Theories, Models and Methods for Analysis of Complex Data for the Brain, (2018/08). Date: April 12, 2018. Time: 8:00 a.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Place: Residence Inn Arlington Capital View, 2850 South Potomac Avenue, Arlington, VA 22202. Contact Person: Dennis Hlasta, Ph.D., Scientific Review Officer, National Institute PO 00000 Frm 00077 Fmt 4703 Sfmt 4703 10499 of Biomedical Imaging and Bioengineering National Institutes of Health, 6707 Democracy Blvd., Bethesda, MD 20892, (301) 451–4794, dennis.hlasta@nih.gov. Dated: March 6, 2018. David Clary, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–04803 Filed 3–8–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Jenish Patel, Ph.D., 240–669–2894; jenish.patel@nih.gov. Licensing information and copies of the U.S. patent application listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301–496–2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications. SUPPLEMENTARY INFORMATION: Technology description follows. SUMMARY: Protein Nanoparticles for Antigen Display in Vaccines Description of Technology The technology relates to a proteinbased nanoparticle platform that allows presentation of immunogenic molecules such as influenza virus antigens. This protein platform is made up of hepatitis B capsid/core proteins. The core proteins contain immunogenic loop c/ e1, where other antigens can be inserted and the chimeric protein retains the ability to form capsid-like particles. The technology describes the insertion of one or more copies of influenza epitopes derived from the globular head or the E:\FR\FM\09MRN1.SGM 09MRN1 10500 Federal Register / Vol. 83, No. 47 / Friday, March 9, 2018 / Notices stem region of hemagglutinin protein into or around the c/e1 loop of the core protein. The nanoparticles formed by the use of Hepatitis B virus core proteins can be disassembled and reassembled, allowing mixing of antigens. Furthermore, the nanoparticles can be expressed in prokaryotic and eukaryotic expression systems. Thus, the platform provides a means for an optimal display of influenza epitopes for the induction of immune response including broadly neutralizing antibodies against the virus and therefore has the potential to be developed into an efficient universal vaccine against influenza virus infection. This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration. Potential Commercial Applications • Vaccine against viruses; vaccines against influenza virus; universal influenza virus vaccine Competitive Advantages • The nanoparticles may be disassembled and re-assembled allowing mixing of antigens • Expression in prokaryotic and eukaryotic systems • Avoids production and usage of live viruses for vaccine generation • Effective immune response due to the use of authentic viral antigens • Stability of particle and immunogenicity after high temperature exposure • Incorporation of epitopes from group 1 and group 2 influenza viruses • Broadly neutralizing antibodies against influenza virus Development Stage • Pre-clinical; in vivo data available (animal) Inventors: Audray K. Harris, Ph.D., (NIAID) and Dustin McCraw, Ph.D., (NIAID). Publications: Gallagher JR, et al., Characterization of the disassembly and reassembly of the HBV glycoprotein surface antigen, a pliable nanoparticle amozie on DSK30RV082PROD with NOTICES CBPL No. 27–03 27–04 27–06 27–08 27–11 Dated: February 27, 2018. Suzanne Frisbie, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. ASTM ASTM ASTM ASTM ASTM Notice is hereby given, pursuant to CBP regulations, that SGS North America, Inc., has been approved to gauge and accredited to test petroleum and petroleum products for customs purposes for the next three years as of August 24, 2017. DATES: The accreditation and approval of SGS North America, Inc., as commercial gauger and laboratory became effective on August 24, 2017. The next triennial inspection date will be scheduled for August 2020. FOR FURTHER INFORMATION CONTACT: Mr. Stephen Cassata, Laboratories and Scientific Services, U.S. Customs and Border Protection, 1300 Pennsylvania Avenue NW, Suite 1500N, Washington, DC 20229, tel. 202–344–1060. SUPPLEMENTARY INFORMATION: Notice is hereby given pursuant to 19 CFR 151.12 and 19 CFR 151.13, that SGS North America, Inc., 12650 McManus Blvd., Suite 103, Newport News, VA 23602, has been approved to gauge and accredited to test petroleum and petroleum products for customs purposes, in accordance with the provisions of 19 CFR 151.12 and 19 CFR 151.13. SGS North America, Inc., is approved for the following gauging procedures for petroleum and certain petroleum products set forth by the American Petroleum Institute (API): SUMMARY: API chapters Title 1 ..................... 3 ..................... 7 ..................... 8 ..................... 12 ................... 17 ................... BILLING CODE 4140–01–P Vocabulary. Tank gauging. Temperature Determination. Sampling. Calculations. Maritime Measurements. DEPARTMENT OF HOMELAND SECURITY U.S. Customs and Border Protection Accreditation and Approval of SGS North America, Inc., as a Commercial Gauger and Laboratory U.S. Customs and Border Protection, Department of Homeland Security. AGENCY: SGS North America, Inc., is accredited for the following laboratory analysis procedures and methods for petroleum and certain petroleum products set forth by the U.S. Customs and Border Protection Laboratory Methods (CBPL) and American Society for Testing and Materials (ASTM): Title D–4006 D–95 D–473 D–86 D–445 27–13 .................. ASTM D–4294 27–48 .................. 27–54 .................. ASTM D–4052 ASTM D–1796 16:47 Mar 08, 2018 Notice of accreditation and approval of SGS North America, Inc., as a commercial gauger and laboratory. ACTION: [FR Doc. 2018–04701 Filed 3–8–18; 8:45 am] ASTM .................. .................. .................. .................. .................. VerDate Sep<11>2014 vaccine platform. Virology, 2017, Feb; 502:176–187 [PMID 28061386]. Intellectual Property: HHS Reference No. E–005–2017/0—U.S. Patent Application No. 62/540,474 filed August 2, 2017. Licensing Contact: Jenish Patel, Ph.D., 240–669–2894; jenish.patel@nih.gov. Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is also seeking statements of capability or interest from parties interested in collaborative research. NIAID would like a prospective collaborator to have one or more of the following capabilities: (1) Capacity to produce recombinant protein for animal vaccine studies; (2) perform and evaluate immunogenicity (antibody response) of influenza vaccine antigens in animal (e.g. mouse models); (3) perform and evaluate challenge and protection studies of vaccines and influenza viruses. (e.g. mouse models); and (4) if results are promising from animal studies, capacity to generate clinical grade materials and perform clinical studies. NIAID will consider executing a Confidentiality Agreement with a prospective collaborator to facilitate receipt of a Capability Statement if requested. For collaboration opportunities, please contact Jenish Patel, Ph.D., 240–669– 2894; jenish.patel@nih.gov. Standard test method for water in crude oil by distillation. Standard test method for water in petroleum products and bituminous materials by distillation. Standard test method for sediment in crude oils and fuel oils by the extraction method. Standard Test Method for Distillation of Petroleum Products. Standard test method for kinematic viscosity of transparent and opaque liquids (and calculations of dynamic viscosity). Standard test method for sulfur in petroleum and petroleum products by energy-dispersive x-ray fluorescence spectrometry. Standard test method for density and relative density of liquids by digital density meter. Standard test method for water and sediment in fuel oils by the centrifuge method (Laboratory procedure). Jkt 244001 PO 00000 Frm 00078 Fmt 4703 Sfmt 4703 E:\FR\FM\09MRN1.SGM 09MRN1

Agencies

[Federal Register Volume 83, Number 47 (Friday, March 9, 2018)]
[Notices]
[Pages 10499-10500]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-04701]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Jenish Patel, Ph.D., 240-669-2894; 
[email protected]. Licensing information and copies of the U.S. 
patent application listed below may be obtained by communicating with 
the indicated licensing contact at the Technology Transfer and 
Intellectual Property Office, National Institute of Allergy and 
Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required 
to receive copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

Protein Nanoparticles for Antigen Display in Vaccines

Description of Technology

    The technology relates to a protein-based nanoparticle platform 
that allows presentation of immunogenic molecules such as influenza 
virus antigens. This protein platform is made up of hepatitis B capsid/
core proteins. The core proteins contain immunogenic loop c/e1, where 
other antigens can be inserted and the chimeric protein retains the 
ability to form capsid-like particles. The technology describes the 
insertion of one or more copies of influenza epitopes derived from the 
globular head or the

[[Page 10500]]

stem region of hemagglutinin protein into or around the c/e1 loop of 
the core protein. The nanoparticles formed by the use of Hepatitis B 
virus core proteins can be disassembled and re-assembled, allowing 
mixing of antigens. Furthermore, the nanoparticles can be expressed in 
prokaryotic and eukaryotic expression systems. Thus, the platform 
provides a means for an optimal display of influenza epitopes for the 
induction of immune response including broadly neutralizing antibodies 
against the virus and therefore has the potential to be developed into 
an efficient universal vaccine against influenza virus infection.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.

Potential Commercial Applications

 Vaccine against viruses; vaccines against influenza virus; 
universal influenza virus vaccine

Competitive Advantages

     The nanoparticles may be disassembled and re-assembled 
allowing mixing of antigens
     Expression in prokaryotic and eukaryotic systems
     Avoids production and usage of live viruses for vaccine 
generation
     Effective immune response due to the use of authentic 
viral antigens
     Stability of particle and immunogenicity after high 
temperature exposure
     Incorporation of epitopes from group 1 and group 2 
influenza viruses
     Broadly neutralizing antibodies against influenza virus

Development Stage

 Pre-clinical; in vivo data available (animal)
    Inventors: Audray K. Harris, Ph.D., (NIAID) and Dustin McCraw, 
Ph.D., (NIAID).
    Publications: Gallagher JR, et al., Characterization of the 
disassembly and reassembly of the HBV glycoprotein surface antigen, a 
pliable nanoparticle vaccine platform. Virology, 2017, Feb; 502:176-187 
[PMID 28061386].
    Intellectual Property: HHS Reference No. E-005-2017/0--U.S. Patent 
Application No. 62/540,474 filed August 2, 2017.
    Licensing Contact: Jenish Patel, Ph.D., 240-669-2894; 
[email protected].
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is also seeking statements of 
capability or interest from parties interested in collaborative 
research. NIAID would like a prospective collaborator to have one or 
more of the following capabilities: (1) Capacity to produce recombinant 
protein for animal vaccine studies; (2) perform and evaluate 
immunogenicity (antibody response) of influenza vaccine antigens in 
animal (e.g. mouse models); (3) perform and evaluate challenge and 
protection studies of vaccines and influenza viruses. (e.g. mouse 
models); and (4) if results are promising from animal studies, capacity 
to generate clinical grade materials and perform clinical studies. 
NIAID will consider executing a Confidentiality Agreement with a 
prospective collaborator to facilitate receipt of a Capability 
Statement if requested. For collaboration opportunities, please contact 
Jenish Patel, Ph.D., 240-669-2894; [email protected].

    Dated: February 27, 2018.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2018-04701 Filed 3-8-18; 8:45 am]
 BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.